研究者業績
  1. 研究者検索結果一覧
  2. 下条 直樹

下条 直樹

シモジョウ ナオキ  (Naoki Shimojo)

基本情報

所属
千葉大学 予防医学センター 千葉大学 (特任教授)
学位
医学博士
J-GLOBAL ID
200901085745097654
researchmap会員ID
1000284693
外部リンク

研究キーワード

 29

研究分野

 5

経歴

 1

論文

 320
  • Yamamoto Takeshi, Endo Yusuke, Onodera Atsushi, Hirahara Kiyoshi, Asou Hikari K, Nakajima Takahiro, Kanno Toshio, Ouchi Yasuo, Uematsu Satoshi, Nishimasu Hiroshi, Nureki Osamu, Tumes Damon J, Shimojo Naoki, Nakayama Toshinori
    NATURE COMMUNICATIONS 9(1) 2018年10月12日  査読有り
  • Daisuke Sawada, Katsunori Fujii, Sonoko Misawa, Tadashi Shiohama, Tomoyuki Fukuhara, Mayuko Fujita, Satoshi Kuwabara, Naoki Shimojo
    Brain and Development 40(9) 830-832 2018年10月  査読有り
  • 山出 晶子, 山本 健, 冨板 美奈子, 下条 直樹, 星岡 明
    日本小児リウマチ学会総会・学術集会プログラム・抄録集 28回 104-104 2018年10月  
  • 山本 健, 山出 晶子, 冨板 美奈子, 下条 直樹, 星岡 明
    日本小児リウマチ学会総会・学術集会プログラム・抄録集 28回 104-104 2018年10月  
  • 佐藤 裕範, 山出 史也, 清水 正樹, 下条 直樹
    日本小児リウマチ学会総会・学術集会プログラム・抄録集 28回 97-97 2018年10月  
  • 古賀 沙織, 照井 エレナ, 諏訪部 信一, 菱木 はるか, 石和田 稔彦, 竹内 典子, 下条 直樹
    小児科診療 81(10) 1373-1376 2018年10月  査読有り
    症例は6歳女児。短腸症候群のため10ヵ月時より中心静脈で栄養管理していた。肺炎球菌による菌血症で入院し、抗菌薬開始後解熱したが、肉眼的血尿と蛋白尿に加え、乏尿と顔面・四肢浮腫、高血圧、低補体血症を認めた。カテーテルを抜去したところ、速やかに解熱、蛋白尿は消失し、顕微鏡学的血尿のみ残存した。中心静脈カテーテル感染症に関連した腎炎では抗菌薬治療に加え、早期のカテーテル抜去が望ましいと考えられた。(著者抄録)
  • Suzuki S, Campos-Alberto E, Morita Y, Yamaguchi M, Toshimitsu T, Kimura K, Ikegami S, Katsuki T, Kohno Y, Shimojo N
    International archives of allergy and immunology 1-8 2018年9月  査読有り
  • 澤田 大輔, 藤井 克則, 小林 弘信, 齋藤 直樹, 江畑 亮太, 内田 智子, 塩濱 直, 下条 直樹
    脳と発達 50(5) 373-373 2018年9月  査読有り
  • 齋藤 直樹, 千葉 文子, 猪口 剛, 三平 元, 仙田 昌義, 岩瀬 博太郎, 下条 直樹
    日本小児科学会雑誌 122(8) 1393-1393 2018年8月  
  • 山出 史也, 下条 直樹
    日本小児アレルギー学会誌 32(3) 426-426 2018年8月  
  • 山出 史也, 佐藤 法子, 藤田 雄治, 中野 泰至, 下条 直樹
    日本小児アレルギー学会誌 32(3) 557-557 2018年8月  
  • 武井 悠, 菱木 はるか, 竹下 健一, 内藤 幸子, 長澤 耕男, 遠藤 真美子, 竹内 典子, 石和田 稔彦, 下条 直樹
    日本小児呼吸器学会雑誌 29(Suppl.) 116-116 2018年8月  査読有り
  • 武井 悠, 石和田 稔彦, 菱木 はるか, 竹下 健一, 藤田 雄治, 大楠 美佐子, 竹内 典子, 鎗田 響子, 亀井 克彦, 渡辺 哲, 下条 直樹
    The Japanese Journal of Antibiotics 71(4) 171-171 2018年8月  査読有り
  • 小林 弘信, 江畑 亮太, 尾本 暁子, 長岡 孝太, 奥主 健太郎, 齋藤 直樹, 下条 直樹
    日本小児循環器学会雑誌 34(Suppl.1) s1-283 2018年7月  
  • 佐藤 法子, 山出 晶子, 石垣 達也, 冨板 美奈子, 星岡 明, 山出 史也, 下条 直樹
    日本小児皮膚科学会雑誌 37(2) 103-107 2018年7月  
    症例は8歳男児。5歳時に左上腕の腫瘤を認め、近医にて経過観察となった。8歳時にそう痒感を伴う腫瘤が増大したため前医を受診し、著明な末梢血好酸球増多、総IgE値上昇を認め、紹介となった。MRIにて左肘上内側皮下にT1強調像で筋肉よりやや高信号、STIR高信号の分葉状腫瘤を認め、生検結果より木村氏病と診断した。外科的切除とステロイド投与を行い、末梢血好酸球数と総IgE値は低下した。木村氏病は、気管支喘息などアレルギー疾患の合併や、カンジダ特異的IgE抗体陽性例が多いことが知られており、疾患の病態に免疫学的機序が関与していることが示唆されている。本症例では腫瘤の増大に先行して、副反応を伴う左上腕へのワクチン接種歴があり、ワクチン接種による免疫反応が木村氏病の発症や増悪に関わった可能性がある。(著者抄録)
  • 佐藤 法子, 山出 史也, 中野 泰至, 原 正美, 下条 直樹
    日本小児臨床アレルギー学会誌 16(2) 275-275 2018年7月  
  • M. Kono, M. Akiyama, Y. Inoue, T. Nomura, A. Hata, Y. Okamoto, T. Takeichi, Y. Muro, W. H.I. McLean, H. Shimizu, K. Sugiura, Y. Suzuki, N. Shimojo
    British Journal of Dermatology 179(1) 190-191 2018年7月  
  • Yuzaburo Inoue, Kanako Mitsunaga, Takeshi Yamamoto, Koki Chiba, Fumiya Yamaide, Taiji Nakano, Yoshinori Morita, Akiko Yamaide, Shuichi Suzuki, Takayasu Arima, Ken-Ichi Yamaguchi, Minako Tomiita, Naoki Shimojo, Yoichi Kohno
    Pediatric rheumatology online journal 16(1) 36-36 2018年6月18日  査読有り
    BACKGROUND: Bisphosphonates are recommended for use as first-line therapy for the prevention and treatment of glucocorticoid-induced osteoporosis in adults. However, the appropriate usage of bisphosphonates for the prevention or treatment of glucocorticoid-induced osteoporosis in children remains unclear. METHODS: We performed a cross-sectional study to clarify the factors associated with the development of glucocorticoid-induced bone loss and osteoporosis in patients with childhood-onset rheumatic disease and to investigate the impact of the early use of alendronate. We recruited 39 patients with childhood-onset rheumatic disease who were evaluated to detect bone loss or osteoporosis at 3 months to 1.5 years after the initiation of treatment. The primary outcome of the study was the presence of bone loss or osteoporosis at the initial evaluation of the bone mineral density after at least 3 months of glucocorticoid therapy. RESULTS: Bone loss and a history of fracture were found in 56 and 18% of the participants, respectively. Weekly oral alendronate therapy (median, 25.4 mg/m2) had been started by the time of the evaluation of osteoporosis in 46% of the participants and within 3 months after the start of glucocorticoid in 31% of the participants. There were no significant differences between the participants with bone loss (wBL group) and without bone loss (w/oBL group) in terms of gender, primary disease, or the age at the onset of primary disease. In terms of glucocorticoid use, there was no significant difference in the age at the start of glucocorticoid therapy, the length of glucocorticoid use, or the dose of glucocorticoids. The proportion of patients in the w/oBL group who received alendronate within 3 months after the start of glucocorticoid therapy was significantly greater than that in the wBL group. In the logistic regression analysis, only "alendronate therapy within 3 months after the start of glucocorticoid therapy" had a statistically significant effect on the development of bone loss (OR, 0.08; 95% CI, 0.02-0.43). The analysis did not reveal any factors associated with the development of osteoporosis. CONCLUSIONS: The early use of alendronate may have a preventive effect against the development of bone loss in glucocorticoid-treated patients with childhood-onset rheumatic disease.
  • Haruka Takei, Naruhiko Ishiwada, Noriko Takeuchi, Misako Ohkusu, Tadashi Hoshino, Shota Murata, Hiroko Sato, Katsuaki Abe, Kenichi Shizuno, Haruka Hishiki, Naoki Shimojo
    Japanese journal of infectious diseases 71(3) 244-246 2018年5月24日  査読有り
    Although invasive meningococcal disease is rare in Japan (0.028 cases per 100,000 population), its incidence is 10 times greater in many other countries. Colonization is a prerequisite for invasive meningococcal disease. However, no study in Japan has involved specifically analyzing the carriage rate of Neisseria meningitidis in children. During 5 months in 2015, the respiratory tract specimens of patients who presented to 3 hospitals with respiratory symptoms were cultured. The bacteria were identified in selective media using a meningococcal detection kit and the serogroup was identified using polymerase chain reaction analysis. In 389 patients aged ≤15 years with respiratory symptoms, the N. meningitidis isolation rate was 0.26% (1/389). The serogroup of the only child who tested positive was Y. In this study, we detected a low meningococcal isolation rate in pediatric patients. Due to increasing globalization, the risk of invasive meningococcal disease is likely increasing in Japan. Accordingly, invasive meningococcal diseases should be continuously monitored in Japan. Future large-scale studies should assess meningococcal isolation rates and corresponding serogroups.
  • 山出 晶子, 山之内 繭, 吉野 有理香, 山本 健, 冨板 美奈子, 下条 直樹, 星岡 明
    アレルギー 67(4-5) 655-655 2018年5月  
  • Nakano Taiji, Dissanayake Eishika, Yamaide Fumiya, Shimojo Naoki
    アレルギー 67(4-5) 494-494 2018年5月  
  • 菅野 雅元, Kong Weng-Sheng, 津山 尚宏, 池田 和貴, 有田 誠, 下条 直樹, 郭 芸, 井上 洋子
    アレルギー 67(4-5) 567-567 2018年5月  
  • 山出 史也, 下条 直樹
    アレルギー 67(4-5) 402-402 2018年5月  
  • 田邉 裕美, 櫻井 健一, 中野 泰至, 渡邉 応宏, 落合 伸伍, 下条 直樹, 森 千里
    アレルギー 67(4-5) 562-562 2018年5月  
  • 藤田 雄治, 有馬 孝恭, 中野 泰至, 山出 史也, 諏訪部 信一, 下条 直樹
    アレルギー 67(4-5) 669-669 2018年5月  
  • Shiohama T, Fujii K, Shimizu K, Ohashi H, Takatani T, Okamoto N, Nishimura G, Kato M, Shimojo N
    Congenital anomalies 58(3) 102-104 2018年5月  査読有り
  • Itoh-Nagato N, Inoue Y, Nagao M, Fujisawa T, Shimojo N, Iwata T, J-OIT group
    Allergology international : official journal of the Japanese Society of Allergology 67(2) 209-216 2018年4月  査読有り
  • Tadashi Shiohama, Hirofumi Ohashi, Kenji Shimizu, Katsunori Fujii, Daiju Oba, Tomozumi Takatani, Mitsuhiro Kato, Naoki Shimojo
    Brain and Development 40(4) 353-356 2018年4月  査読有り
  • 海老澤 元宏, 伊藤 浩明, 今井 孝成, 大矢 幸弘, 大嶋 勇成, 下条 直樹, 藤澤 隆夫, 大久保 公裕, 中村 陽一, 福冨 友馬, 山口 正雄, 相原 道子, 古江 増隆
    AMED 難治性疾患等実用化研究事業免疫アレルギー疾患等実用化研究事業 2018年4月  
  • 佐藤 法子, 山出 史也, 中野 泰至, 下条 直樹
    日本リウマチ学会総会・学術集会プログラム・抄録集 62回 687-687 2018年3月  
  • Tomoyuki Fukuhara, Katsunori Fujii, Tomoko Ogawa, Tadashi Shiohama, Naoki Shimojo
    Pediatrics International 60(2) 198-199 2018年2月  査読有り
  • Takeshita Kenichi, Ishiwada Naruhiko, Takeuchi Noriko, Takahashi Yoshiko, Naito Sachiko, Nagasawa Koo, Hishiki Haruka, Hoshino Tadashi, Shimojo Naoki
    The Japanese Journal of Antibiotics 71(1) 13-21 2018年2月  
    造血器腫瘍または固型腫瘍にて経過観察中の小児41名(5〜18歳)から血清試料を採取し、肺炎球菌PCV13(非PCV7)血清型に対する特異的抗体を測定した。患児はいずれもPCV13接種を受けていなかった。6つの血清型すべてについて患児のIgGレベルは同年齢の健常対照と比べて低かった。採血前6ヵ月以内に化学療法を受けた患児では他の患児と比べて血清型特異的IgGレベルが低かった。以上より、年齢を理由に定期的ワクチン接種を推奨されていない免疫不全状態の小児の多くにおいて、侵襲性肺炎球菌感染症の予防に十分なPCV13血清型特異的IgG値に達していないことが判明した。
  • 山出 史也, 戸村 円, 鈴木 洋一, 下条 直樹
    日本小児科学会雑誌 122(2) 274-274 2018年2月  
  • Fujisawa, Takao, Nagao, Mizuho, Mizuno, Yumi, Shimojo, Naoki, Itoh-Nagato, Natoka, Ohya, Yukihiro, Imai, Takanori, Ebisawa, Motohiro, Habukawa, Chizu, Odajima, Hiroshi, Sato, Yasunori
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 141(2) AB222-AB222 2018年2月  
  • Kawashima T, Ikari N, Watanabe Y, Kubota Y, Yoshio S, Kanto T, Motohashi S, Shimojo N, Tsuji NM
    Frontiers in immunology 9 27 2018年1月23日  査読有り
  • Takahiro Aoki, Masashi Kyushiki, Hiroshi Kishimoto, Masato Yanagi, Makiko Mori, Yuki Arakawa, Moeko Hino, Naoki Shimojo, Katsuyoshi Koh
    Journal of Pediatric Hematology/Oncology 40(4) 334-335 2018年  査読有り
  • Sakura Sato, Chizuko Sugizaki, Noriyuki Yanagida, Komei Ito, Yusei Ohshima, Naoki Shimojo, Takao Fujisawa, Motohiro Ebisawa
    Allergology International 67(3) 399-404 2018年  査読有り
    Background: Clinical trials on oral immunotherapy (OIT) have been increasing for nearly a decade however, several national guidelines do not recommend OIT as a standardized procedure. The aim of this study was to obtain insights into the current use and practice of OIT in Japan. Methods: A first questionnaire was mailed to 524 training and teaching facilities of the Japan Pediatric Society. The first survey requested information on the implementation of OIT, whereas the second survey aimed to gather more detailed information on OIT, such as its safety. Results: In total, 360 facilities (69%) responded to the survey among them, 102 (28%) provided OIT to 7973 patients [1544 received OIT while hospitalized (inpatient OIT), whereas 6429 received OIT without hospitalization (outpatient OIT)]. Approval for OIT was obtained from an ethics committee or institutional review board in 89% and 31% of facilities for inpatient and outpatient OIT, respectively. In inpatient OIT, immediate allergic reactions requiring treatment occurred in 68% of patients while hospitalized, and in another 56%, following discharge. In contrast, 11% of patients developed immediate allergic reactions in outpatient OIT. Adrenaline injections at home were required in 2%. Sixteen patients developed adverse reactions other than immediate allergic reactions, among which eosinophilic gastroenteritis was most common. Conclusions: OIT is widely provided not only as clinical research but also as general practice in Japan. However, because there is a high risk of developing anaphylaxis at home, OIT should be conducted carefully as in a clinical research setting taking safety into consideration.
  • Kazuyuki Sogawa, Yuria Takahashi, Yui Shibata, Mamoru Satoh, Yoshio Kodera, Fumio Nomura, Toshio Tanaka, Hironori Sato, Fumiya Yamaide, Taiji Nakano, Kazuhiko Iwahashi, Yoshiko Sugita-Konishi, Akinori Shimada, Naoki Shimojo
    International archives of allergy and immunology 176(3-4) 189-197 2018年  査読有り
    BACKGROUND: Food allergy is a serious health issue affecting roughly 4% of children, with a substantial effect on quality of life. Chicken egg allergy is frequently observed in infants. Therefore, some of them have to exclude hen's eggs from their daily diet to avoid allergenic symptoms. Hen's egg is composed of 2 soluble parts; one is egg white, which has been characterized as the major source of allergenicity, while the other is egg yolk, which is estimated as a miner source. Only 2 allergens from egg yolk, α-livetin (Gal d 5) and YGP42 (Gal d 6), have been described to date. METHODS: Sera from 53 patients allergic to hen's eggs and 2 patients allergic to sesame were obtained from the Department of Pediatrics, Chiba University Hospital. The study was performed using SDS-PAGE, IgE immunoblotting, and dot blotting. RESULTS: Seven bands of egg yolk were detected by IgE immunoblotting. Out of these bands, a possible new allergen was further characterized by LC-MS/MS. The 33-kDa band was identified as yolk glycoprotein (YGP40) by LC-MS/MS. A total of 21 of the 53 patients (47%) had YGP40 detected by dot blotting. CONCLUSIONS: We identified YGP40 as a new hen's egg yolk allergen and detected 4 sites of YGP40 as linear epitopes.
  • Morita Y, Campos-Alberto E, Yamaide F, Nakano T, Ohnisi H, Kawamoto M, Kawamoto N, Matsui E, Kondo N, Kohno Y, Shimojo N
    Frontiers in pediatrics 6 162 2018年  査読有り
  • Mizuho Nagao, on behalf of the, Masanori Ikeda, Norimasa Fukuda, Chizu Habukawa, Tetsuro Kitamura, Toshio Katsunuma, Takao Fujisawa, Kennichi Tokuyama, Akihiko Terada, Kazuki Sato, Katsushi Miura, Hirokazu Arakawa, Masafumi Zaitsu, Tastuo Sakamoto, Tetsuya Takamasu, Naoki Shimojo, Makoto Kameda, Hiroyuki Mochizuki, Hiroshi Tachimoto, Koichi Yamaguchi, Kei Masuda, Yuichi Adachi, Yusei Oshima, Shigemi Yoshihara, Noriko Tanaka, Kunitaka Ohta, Masao Morita, Reiko Tokuda, Yoshihiko Kitou, Hayao Araki, Akiko Yamaoka, Akio Nakamura
    Allergology International 67(1) 72-78 2018年1月1日  査読有り
    Background While Japanese guideline recommends initial control treatment for preschool children with asthma symptoms more than once a month, Western guidelines do not. To determine whether control treatment with montelukast was more effective than as-needed β2-agonists in this population, we conducted a randomized controlled trial. Methods Eligible patients were children aged 1–5 years who had asthma symptoms more than once a month but less than once a week. Patients were randomly assigned in a 1:1 ratio to receive montelukast 4 mg daily for 48 weeks or as-needed β2-agonists. The primary endpoint was the number of acute asthma exacerbations before starting step-up treatment with inhaled corticosteroids. This study is registered with the University Hospital Medical Information Network clinical trials registry, number UMIN000002219. Results From September 2009 to November 2012, 93 patients (47 in the montelukast group and 46 in the no-controller group) were enrolled into the study. All patients were included in the analysis. During the study, 13 patients (28%) in the montelukast group and 23 patients (50%) in the no-controller group had acute exacerbations with the mean numbers of 0.9 and 1.9/year, respectively (P = 0.027). In addition, 10 (21%) and 19 (41%) patients received step-up treatment, respectively. Cumulative incidence of step-up treatment was significantly lower in the montelukast group (hazard ratio 0.45, 95% confidence interval 0.21 to 0.92 P = 0.033). Conclusions Montelukast is an effective control treatment for preschool children who had asthma symptoms more than once a month but less than once a week.
  • Takatani T, Shiohama T, Takatani R, Shimojo N
    Human genome variation 5 30-30 2018年  査読有り
  • 日野 もえ子, 石和田 稔彦, 青木 孝浩, 岡田 玲緒奈, 奥主 朋子, 大楠 美佐子, 渡邉 哲, 亀井 克彦, 下条 直樹
    日本小児血液・がん学会雑誌 55(2) 171-176 2018年  
    <p>小児がん患者では，真菌感染症が疑われる場合でも，真菌の分離同定はしばしば困難であり臨床経過により診断治療が行われることが多い．2004年1月から2014年12月までに当科で治療を受けた小児血液がん患者6人より分離同定された糸状菌2株，酵母5株に関し，薬剤感受性試験を行い，分離同定することの意義について後方視的に検討した．糸状菌はいずれも耳漏より検出された．1例では好中球抑制期間に外耳炎を繰り返し，<i>Aspergillus terreus</i>が同定された．薬剤感受性試験の結果よりミカファンギン（MCFG），ボリコナゾール（VRCZ）を併用し造血幹細胞移植を行った．酵母はすべてカンジダで，血液より分離同定された．<i>Candida tropicalis</i>分離例は治療開始後にβ-Dグルカンの上昇，脾膿瘍の悪化を認めたが感受性試験にてMCFG感受性良好であることを確認し治療遂行できた．<i>C. parapsilosis</i>，<i>C. glabrata</i>分離例はいずれもMCFG投与下のブレイクスルー感染であった．MCFG感受性良好として知られている<i>C. glabrata</i>に関しては薬剤感受性試験の結果，キャンディン系薬剤に対するMICの上昇が確認された．近年米国でもキャンディン系耐性カンジダが問題となっており，今後小児がん患者においても，治療効果が思わしくない際には薬剤感受試験を行うことが必要だろう．</p>
  • Tomoaki Ando, Jun-ichi Kashiwakura, Naoka Itoh-Nagato, Hirotaka Yamashita, Minato Baba, Yu Kawakami, Shih Han Tsai, Naoki Inagaki, Kiyoshi Takeda, Tsutomu Iwata, Naoki Shimojo, Takao Fujisawa, Mizuho Nagao, Kenji Matsumoto, Yuko Kawakami, Toshiaki Kawakami
    JOURNAL OF CLINICAL INVESTIGATION 127(12) 4541-4553 2017年12月  査読有り
    Food allergy occurs due to IgE- and mast cell-dependent intestinal inflammation. Previously, we showed that histamine-releasing factor (HRF), a multifunctional protein secreted during allergy, interacts with a subset of IgE molecules and that the HRF dimer activates mast cells in an HRF-reactive IgE-dependent manner. In this study, we investigated whether HRF plays any role in food allergy. Specifically, we determined that prophylactic and therapeutic administration of HRF inhibitors that block HRF-IgE interactions reduces the incidence of diarrhea and mastocytosis in a murine model of food allergy. Food allergy-associated intestinal inflammation was accompanied by increased secretion of the HRF dimer into the intestine in response to proinflammatory, Th2, and epithelial-derived cytokines and HRF-reactive IgE levels at the elicitation phase. Consistent with these data, patients with egg allergy had higher blood levels of HRF-reactive IgE compared with individuals that were not hypersensitive. Successful oral immunotherapy in egg-allergy patients and food-allergic mice reduced HRF-reactive IgE levels, thereby suggesting a pathological role for HRF in food allergy. Together, these results suggest that antigen and HRF dimer amplify intestinal inflammation by synergistically activating mast cells and indicate that HRF has potential as a therapeutic target in food allergy.
  • 萩原 翔, 岩倉 英雄, 佐藤 裕範, 江畑 亮太, 遠藤 真美子, 大曽根 義輝, 下条 直樹
    日本小児科学会雑誌 121(12) 2026-2027 2017年12月  
  • 長岡 孝太, 齋藤 直樹, 小林 弘信, 奥主 健太郎, 江畑 亮太, 福原 知之, 藤田 真祐子, 塩濱 直, 藤井 克則, 下条 直樹
    日本小児科学会雑誌 121(12) 2026-2026 2017年12月  査読有り
  • Traina G, Valluzzi RL, Fierro V, Riccardi C, Artesani MC, De Vuono A, Fiocchi A, Martelli AG, Ríos LA, Alcocer CR, Navarrete E, Del Rio, Navarro BE, Gonzalez V, Velasco B, Perez Aviles HJ, Fernandez RJ, Pozo FC, Farhan AJ, Arshad H, Hussain A, Sharikadze O, Okhotnikova O, Alcover J, Rodriguez D, Pineda F, Dalal I, Weinbra, d-Goichberg J, Benor S, Rottem M, Kivity S, Sato S, Yanagida N, Ebisawa M, Umanets T, Pineda F, Antipkin Y, Barzylovich V, Lapshyn V, Umanets T, Umanets M, Yuriev S, Pineda F, Rodriguez D, Alcover J, Bekir S, Pincock T, Vieira Hernandez A, Capriles Hulett A, Sánchez Borges M, Fabiano F, Albarran C, Goyal R, Gupta S, Gaurav G, Luskin AT, Griffin NM, Wagelie-Steffen A, Trzaskoma BL, Limb SL, Busse WW, Zeiger RS, Gonzalez-Reyes E, Casale TB, Chipps BE, Sugizaki C, Goto F, Sato S, Yanagida N, Ebisawa M, Yamaide A, Mitsunaga K, Tomiita M, Hoshioka A, Shimojo N, Pop LL, Ciucǎ IM, Tǎmaş L, Lazarescu M, Pienar C, Yamaide F, Fikri B, Sato H, Shimojo N, Okishima N, Kobayashi M, Takai M, Nishigata K, Yoda R, Oana YT, Kajiwara C, Shimodaira M, Suzuki T, Iizawa H, Kamijo K, Karmakar B, Bhattacharya SG, Blohlávková S, Kopelentová E, Víšek P, tádler J, Šetinová I, Novobílská J, Lundelin K, Salminen S, Isolauri E, Pitt T, Flanders T, Peñalver M, Martínez P, Lluch M, Malet A, Nam YH, Jin HJ, Lee SK, Kulalert P, Sritipsukho P, Pathumanond J, Baynova K, Labella M, De Aramburu T, Prados M, Haanpää L, Aarnio J, Nermes M, Af Ursin P, Kaljonen A, Isolauri E, Bala N, Bhagwat K, Hindley J, Chapman M, Baalasubramanian S, Besednjak-Kocijančič L, SenGupta K, Bhattacharya SG, Chipps BE, Antonova E, Kong AM, Iqbal A, Teague WG, Chipps BE, Antonova E, Trzaskoma B, Ortiz B, Paknis B, Iqbal A, Rosen K, Szefler S, Alblooshi A, Al-Hammadi S, Vega A, Gutiérrez-Rivas R, Alonso AM, Beitia JM, Belén Mateo M, Cárdenas R, García-Domínguez JJ, Pitchon Dos Reis R, Gonçalves Alvim C, Andrade C, Reis A, Ribeiro H, Panaitescu Bunu C, Marusciac L, Paralescu S, Tamas P, Panitescu Bunu C, Marusciac L, Paralescu S, Tamas P, Martí, Guadaño E, Escobar Bolaños C, Martí José N, Pau Casanovas P, Biarnés Rib G, Castells M, de Vicente Jiménez T, Mennini M, Riccardi C, De Angelis P, Rea F, Malamisura M, Tambucci R, Fiocchi A, Dall'Oglio L, Mennini M, Del Chierico F, Napolitano T, Reddel S, Vernocchi P, D'Ambrosio A, Putignani L, Artesani MC, Dahdah L, Fierro V, Banzato C, Echeverría Zudaire LA, Plaza AM, Bosque García M, Íbero M, Mazzina O, Fierro V, Marzano V, Riccardi C, Mazzina O, Dahdah L, Mennini M, Artesani MC, Mazzina O, Pecora V, Koch P, Valluzzi RL, Fierro V, Fiocchi A, Pecora V, Valentini D, Mennini M, Dahdah L, Mazzina O, Santamaria F, Valluzzi R, Mukherjee A, Kandhare A, Bodhankar S
    WORLD ALLERGY ORGANIZATION JOURNAL 10(Suppl 2) 39 2017年11月  査読有り
  • Naoki Shimojo, Kenji Izuhara
    ALLERGOLOGY INTERNATIONAL 66(4) 513-514 2017年10月  査読有り
  • 山本 健, 山出 晶子, 冨板 美奈子, 下条 直樹, 星岡 明
    日本小児リウマチ学会総会・学術集会プログラム・抄録集 27回 80-80 2017年10月  
  • Nakano Taiji, Dissanayake Eishika, Yamaide Fumiya, Shimojo Naoki
    日本小児アレルギー学会誌 31(4) 545-545 2017年10月  
  • Fikri Bahrul, Tomura Madoka, Mitsuishi Chisako, Tani Yumi, Sahara Masumi, Nakano Taiji, Yamaide Fumiya, Shimojo Naoki
    日本小児アレルギー学会誌 31(4) 545-545 2017年10月  

MISC

 1290
もっとみる

書籍等出版物

 3

共同研究・競争的資金等の研究課題

 16
もっとみる

産業財産権

 5
一覧へ戻る